SCHEMBL4021233

SCHEMBL4021233

CCCCCCCCCCCCNS(=O)(=O)c1ccc(CN(OOC(=O)COC(C)=O)C2CCCC2)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
HTT P42858 2/20 0.41
TSHR P16473 1/20 0.41
NPY1R P25929 1/20 0.35
NPY2R P49146 1/20 0.35
GAA P10253 1/20 0.35
MAPK1 P28482 2/20 0.32
FAAH O00519 1/20 0.32
LMNA P02545 2/20 0.31
ALDH1A1 P00352 3/20 0.31
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31
PSENEN Q9NZ42 1/20 0.31
CA12 O43570 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021235 0.81 SMN1; SMN2 (0.45) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL5044430 0.78 KMT2A (0.52) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL1851100 0.77 SMN1; SMN2 (0.44) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL1855668 0.76 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL1854872 0.69 KMT2A (0.55) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL1856185 0.68 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL4715407 0.67 SMN1; SMN2 (0.69) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL1851101 0.67 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL6719223 0.66 SMN1; SMN2 (0.49) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL1852856 0.66 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AMEN1HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed
EP-1986637-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS Laboratoires Serono SA (CH) 2008-11-05 EP disclosed
WO-2007093557-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS LABORATOIRES SERONO S.A. (CH) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections STS, TST, SULT1A1 SMN1; SMN2 2147/4885KMT2A 2981/4885MEN1 2947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.